by Kelley Tracy | Mar 3, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Inhibitors of the PHD2 Zinc Finger to Treat Anemia,” Jay Wrobel, Principal Investigator, in collaboration with Prof. Frank Lee of the University of...
by Kelley Tracy | Feb 23, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Entered Into a Sponsored Research Agreement with Biohaven Pharmaceutical Holding Company, Ltd. Whereby FCCDC Would Perform Certain Research Services to Advance Biohaven Projects in Neurology, Cancer and Pain....
by Kelley Tracy | Feb 17, 2017 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant from the National Eye Institute of the National Institutes of Health, Entitled “Development of a Novel Antiviral to Treat and Prevent Acyclovir Resistance in Human Ocular...
by Kelley Tracy | Aug 15, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as the PI, Entitled “Small Molecule Antagonists of PF4 for the Treatment...
by Kelley Tracy | Aug 15, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as the PI, Entitled “Small Molecule Antagonists of PF4 for the Treatment...
by Kelley Tracy | Jul 5, 2016 | Uncategorized
The Fox Chase Chemical Diversity Center Announces that the FDA has Completed its Review of FC-4157 (also known as BHV-4157) Investigational New Drug Application (IND) Filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd Doylestown, PA. July 5,...
